Cargando…

A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design

Antibody drug conjugates (ADCs) represent novel anti-cancer modalities engineered to specifically target and kill tumor cells expressing corresponding antigens. Due to their large size and their complex kinetics, these therapeutic agents often face heterogeneous distributions in tumors, leading to l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasalou, Christina, Helmlinger, Gabriel, Gomes, Bruce
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364906/ https://www.ncbi.nlm.nih.gov/pubmed/25786126 http://dx.doi.org/10.1371/journal.pone.0118977

Ejemplares similares

Mechanistic Modeling of Intra‐Tumor Spatial Distribution of Antibody‐Drug Conjugates: Insights into Dosing Strategies in Oncology
por: Weddell, Jared, et al.
Publicado: (2020)

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
por: Lu, Guolan, et al.
Publicado: (2020)

Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation
por: Nilchan, Napon, et al.
Publicado: (2019)

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
por: Lu, Dan, et al.
Publicado: (2014)

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
por: Peskov, Kirill, et al.
Publicado: (2019)

Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation
por: Christie, R. James, et al.
Publicado: (2017)

A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors
por: Wu, Yanling, et al.
Publicado: (2022)

Antimicrobial and Cell-Penetrating Peptides: Understanding Penetration for the Design of Novel Conjugate Antibiotics
por: Hadjicharalambous, Andreas, et al.
Publicado: (2022)

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)

Insights into the Membranolytic Activity of Antimalarial Drug-Cell Penetrating Peptide Conjugates
por: Aguiar, Luísa, et al.
Publicado: (2020)

Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology
por: Feld, Jonathan, et al.
Publicado: (2013)

Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)
por: Yao, Houzong, et al.
Publicado: (2016)

Comparing Variants of the Cell-Penetrating Peptide sC18 to Design Peptide-Drug Conjugates
por: Grabeck, Joshua, et al.
Publicado: (2022)

A Multiscale Model to Investigate Circadian Rhythmicity of Pacemaker Neurons in the Suprachiasmatic Nucleus
por: Vasalou, Christina, et al.
Publicado: (2010)

Molecular Dynamics Simulations of Drug-Conjugated Cell-Penetrating Peptides
por: Ivánczi, Márton, et al.
Publicado: (2023)

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017)

Imaging mass spectrometry for the precise design of antibody-drug conjugates
por: Fujiwara, Yuki, et al.
Publicado: (2016)

Marine Antibody–Drug Conjugates: Design Strategies and Research Progress
por: Wang, Yu-Jie, et al.
Publicado: (2017)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

Penetration of Nanobody-Dextran Polymer Conjugates through Tumor Spheroids
por: Bitsch, Peter, et al.
Publicado: (2023)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Mechanistic insights into the rational design of masked antibodies
por: Orozco, Carolina T., et al.
Publicado: (2022)

Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates
por: Zwaagstra, John C., et al.
Publicado: (2019)

Antibody–drug conjugates as novel anti-cancer chemotherapeutics
por: Peters, Christina, et al.
Publicado: (2015)

A FZD7-specific Antibody–Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models
por: Do, Myan, et al.
Publicado: (2022)

A Generic Mechanism for Enhanced Cytokine Signaling via Cytokine-Neutralizing Antibodies
por: Shulgin, Boris, et al.
Publicado: (2016)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Design of Quorum Sensing Inhibitor–Polymer Conjugates to Penetrate Pseudomonas aeruginosa Biofilms
por: Soukarieh, Fadi, et al.
Publicado: (2023)

Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases
por: Yap, May Lin, et al.
Publicado: (2019)

The influence of degree of labelling upon cellular internalisation of antibody-cell penetrating peptide conjugates
por: Pringle, Toni A., et al.
Publicado: (2022)

Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting
por: Evans, Reginald, et al.
Publicado: (2022)

Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate
por: Pouzin, Clemence, et al.
Publicado: (2022)

Design of new acid-activated cell-penetrating peptides for tumor drug delivery
por: Yao, Jia, et al.
Publicado: (2017)

PDL-1 Antibody Drug Conjugate for Selective Chemo-Guided Immune Modulation of Cancer
por: Sau, Samaresh, et al.
Publicado: (2019)

DIPG-41. EXPLORING BRAIN PENETRANT PEPTIDE-DRUG CONJUGATES IN DIFFUSE INTRINSIC PONTINE GLIOMA MODELS
por: Clark, Jasmine, et al.
Publicado: (2023)

Anti-SSTR2 Antibody-drug Conjugate for Neuroendocrine Tumor Therapy
por: Si, Yingnan, et al.
Publicado: (2020)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

A Rationally Designed ICAM1 Antibody Drug Conjugate for Pancreatic Cancer
por: Huang, Jing, et al.
Publicado: (2020)

CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
por: Domínguez, Juan Manuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_89u1mbdhc34hkrmsfv1d0i0olp